Guggenheim RX 2023?
Any update on Guggenheim RX in 2023? Have heard great culture/people things surrounding Guggenheim as a whole, so I'd be willing to bet that extends to RX. Any insight into exit opportunities and hours would be greatly appreciated. They seem to be relatively new but are starting to establish themselves, so curious about their trajectory within RX as well as where junior analysts/associates have or can exit to. As a Tier 2 shop clearly behind EVR/HL/PJT, is this at all limiting to where you can exit into? Or is the restructuring space so niche that you'll be given the same opportunities?
Bump
You'll be given the same credit (Vanilla/Distressed) opps as those other places listed. Buyout might be a bit harder.
hi, just posted a topic on Rx exits in the credit forum. Would you mind taking a brief moment to elaborate on credit exits (key funds/players, key strategies, recruiting, etc.) either here or in the new topic? Feel like even within RX, MF PE seems to be so common, and I'm curious to hear an in-depth description of the credit landscape. I would greatly appreciate it - thank you for any amount of time/effort you can give
bump
Killing it recently. Lots of good debtor side mandates like cyxtera, rite aid, instant brands. Obviously makes hours tougher. Exits into credit same as t1, probably worse for PE
Decent Rx shop, behind all the EBs. Even CVP. Exits will be credit focused, havnt really seen any UMM/MF PE exits.
within credit, what type of exits have you seen?
Tempore tempora sint culpa sed. Hic laudantium ducimus quidem quidem quaerat ratione. Voluptatem tenetur tempora aut.
Eveniet deleniti nulla ut maxime facere reprehenderit. Harum quam error ducimus aperiam. Quaerat eligendi maxime in non incidunt omnis. Ut non suscipit illum excepturi dolorem excepturi.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...